Atrioventricular septal defect prevention

Jump to navigation Jump to search

Atrioventricular septal defect Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Atrioventricular septal defect from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

MRI

CT

Echocardiography

Cardiac Catheterization

Treatment

Medical Therapy

Surgery

Prevention

Pregnancy

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Atrioventricular septal defect prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atrioventricular septal defect prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atrioventricular septal defect prevention

CDC on Atrioventricular septal defect prevention

Atrioventricular septal defect prevention in the news

Blogs on Atrioventricular septal defect prevention

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Atrioventricular septal defect prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Prevention

2008 ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease (DO NOT EDIT)[1]

Recommendations for Endocarditis Prophylaxis (DO NOT EDIT)[1]

Class III
"1. Prophylaxis against IE is not recommended for nondental procedures (such as esophagogastroduodenoscopy or colonoscopy) in the absence of active infection. (Level of Evidence: C)"
Class IIa
"1. Antibiotic prophylaxis before dental procedures that involve manipulation of gingival tissue or the periapical region of teeth or perforation of the oral mucosa is reasonable in patients with CHD with the highest risk for adverse outcome from IE, including those with the following indications:"
"a. Prosthetic cardiac valves or prosthetic material used for cardiac valve repair. (Level of Evidence: B)"
"b. Previous IE. (Level of Evidence: B)"
"c. Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits. (Level of Evidence: B)"
"d. Completely repaired CHD with prosthetic materials, whether placed by surgery or by catheter intervention, during the first 6 months after the procedure. (Level of Evidence: B)"
"e. Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device that inhibit endothelialization. (Level of Evidence: B)"
"2. It is reasonable to consider antibiotic prophylaxis against IE before vaginal delivery at the time of membrane rupture in select patients with the highest risk of adverse outcomes. This includes patients with the following indications:"
"a. Prosthetic cardiac valves or prosthetic material used for cardiac valve repair. (Level of Evidence: C)"
"b. Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits. (Level of Evidence: C)"

References

  1. 1.0 1.1 Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.

Template:WH Template:WS CME Category::Cardiology